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Severe dialyzer dysfunction undetectable by standard reprocessing
validation tests. It is generally accepted that careful monitoring of total
cell volume and ultrafiltration rates will ensure adequate function of
reprocessed dialyzers. During routine urea kinetic measurements we
noted that the percent of patients with clearances less than 200 mI/mm
increased from 5% to 48% despite adherence to these validation tests.
As these patients did not have evidence of recirculation in the vascular
access, possible causes of dialyzer dysfunction were investigated.
Injection of methylene blue into the dialysate port revealed non-uniform
flow of dialysate in dialyzers from patients with markedly reduced
clearances. In vitro studies of dialyzers subjected to sequential daily
reprocessing, without patient exposure, demonstrated that in vitro
clearances declined in one lot but not another. The initial clearances of
218 4mI/mm fell progressively to 112 18 (P <0.001) after IS reuses.
No effects of reprocessing were found in a different lot (230 2 vs. 226
4 mI/mm). Soaking the dialyzers from the affected lot in either the
disinfectant or dialysate solution caused a decline in the clearances
which was less than that of serial reuse. Although the magnitude of the
problem of dialyzer malfunction with reuse is unknown, careful atten-
tion to dialyzer function is warranted in patients treated with repro-
cessed dialyzers.
Since Shaldon, Silva and Rosen [1] first described reuse of
dialyzers in 1964, there has been increasing and widespread
acceptance of the procedure. It is estimated that 70% of patients
in the United States are currently treated with dialyzers under-
going some form of reprocessing [2]. During routine urea kinetic
studies, we recently noted an alarming decline in the clearances
of patients treated with reprocessed dialyzers. This occurred
without alterations in standard validation tests used to judge
dialyzer function. We, therefore, attempted to define the prob-
lem and identify possible causes to account for the observation.
Methods
The Chromalloy American Kidney Center is a 28 station, 160
patient, free-standing dialysis unit owned and operated by
Washington University School of Medicine. High-efficiency
dialysis was performed on 97% of patients using Fresenius
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A2008 C or A2008 D machines (Seratronics, Concord, Califor-
nia, USA). Maximum blood flow rates ranged from 400 to 430
mI/mm and dialysate flow rates from 500 to 800 ml/min. Urea
kinetics were performed routinely every two months and the
dialysis prescription was altered as necessary to maintain a
KT/V of greater than 1.0 [3]. The mean duration of dialysis was
2.6 hours (range 2 to 4 hours). Sixty-eight percent of patients
were dialyzed with Clirans TAF 12 (Terumo Corp., Japan) and
19 percent with Clirans TAF 10 dialyzers. All but one patient
were treated with dialyzers which were reprocessed with DRS
4 Dialyzer Reprocessing System (Seratronics). The details of
the system are described elsewhere [4]. In brief, this was a
multi-station, automated reprocessing system which employed
several rinses with reverse ultrafiltration transmembrane pres-
sures as high as 1200 mm Hg (fiber intraluminal pressure
negative). Bleach (sodium hypochiorite), at a maximum con-
centration of 0.75%, and an exposure time of six minutes, was
employed as a cleansing agent. Glutaraldehyde (0.8%) (Ne-
phrex, Surgicos, Arlington, Texas) was used for disinfection
and storage. All steps were performed according to manufac-
turers' recommendations. The reprocessing procedure began
within 10 minutes of termination of dialysis in the vast majority
of cases. Dialyzers were discarded if any of the following
rejection criteria were met: 1) total cell volume (TCV) less than
80% of the initial TCV (TCV is sometimes also referred to as
"fiber bundle volume"); 2) ultrafiltration rates (UFR) less than
75% of the initial UFR; 3) evidence of a pressure leakage; or 4)
greater than 15 clotted fibers on visual inspection. The mean
number of reuses with this system was 19 (range 1 to 50).
Chromalloy-St. Anthony's Dialysis Center is a small, six
station dialysis unit managed by Washington University School
of Medicine. Patients were dialyzed with Centry 2 Rx (Cobe
Laboratories, Inc., Lakewood, Colorado, USA) machines and
Clirans dialyzers provided by Chromalloy American Kidney
Center. Dialyzers were reprocessed with a Renatron RS 8300
(Renal Systems, Minneapolis, Minnesota, USA) single-station
reprocessing device. This system employed several rinse steps
with maximal reverse ultrafiltration transmembrane pressures
of 250 mm Hg. Validation tests of dialyzer function were the
same as the Seratronics system except for the absence of KUF
monitoring. Renalin (Renal Systems), a formulation of peracetic
acid, was used for disinfection.
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Clearance measurements
The in vivo urea clearances were derived from urea kinetic
modeling as described in detail by Gotch and Sargent [3]
according to the formula:
K = — [in (I —)JT Co
where V = volume of distribution of urea (ml), T = time
(minutes), zC = absolute decline in BUN with dialysis (mg/dl),
and Co predialysis BUN (mg!dl). Pre- and post-dialysis BUN
levels were obtained twice during the same week for calculation
of the clearances which were not corrected for access recircu-
lation. The results were averaged in each patient. Total body
water was estimated from the calculated surface area of each
patient [5].
The in vitro low molecular weight clearances of the dialyzers
were estimated using conductivity measurement technique
[6,7]. This simple method involves the perfusion of dialysate
through the dialysate side of the dialyzer and water (treated
with reverse osmosis and deionization) through the "blood"
path. In this non-recirculating system, the dialysate flow rate
(QD) averaged 525 mI/mm. The water flow rate (QB) was set at
300 ml/min. Both were measured with graduated cylinders over
five minutes prior to each testing. The results were used in the
calculation of clearances. Conductivity readings (80 BC West-
ern Meter, Mesa Medical, Wheatridge, Colorado, USA) were
determined, after a suitable equilibrium period (usually 15 mm)
from the dialysate outflow (CDO), dialysate inflow (CDI) and
venous (CBO) lines. The clearances assume zero ultrafiltration
and are given by the formulae:
—
QB(CBO)K8 - _____
CDI
— QD(CDI — C00)KD — ___________
CDI
where K8 equals clearance on the blood side and KD equals
clearance on the dialysate side. Mass balance, obtained by
dividing KB by KD was 1.071 0.005. The interassay coeffi-
cient of variation for KB in unreprocessed dialyzers was 3.14%.
All in vitro clearances reported are derived from KB and were
performed in a blinded fashion.
In vitro studies
The effect of reprocessing on dialyzer function in the absence
of patient exposure was assessed. Dialyzers from a lot judged to
be associated with low in vivo clearances (lot #1) were com-
pared to a log which was associated with the expected in vivo
clearances (lot #2).
Experiment 1. Clearances were measured in unused, unre-
processed dialyzers from both lots. All dialyzers then under-
went daily reprocessing in a fashion identical to that described
above. Clearances were obtained after 5, 10, and 15 reprocess-
ing procedures.
Experiment 2. Clearances in lot #1 were measured after 0, 1,
3, and 5 reprocessing procedures.
Experiment 3. Clearances from unused dialyzers in lots 1 and
2 were measured. Clearances were then repeated following
soaking the dialyzers in either glutaraldehyde or dialysate for
five days.
Table 1. Biochemical determinants
Creatinine BUN .Potassium
mEqilitermg/dl
Period A
Unaffected group 11.8 0.6 70.9 2.9 4.50 0.08
Affected group 12.4 0.5 73.0 3.1 4.76 0.12
Period B
Unaffected group 11.8 0.5 71.6 2.8 4.59 0.09
Affected group 14.2 0.6a 86.1 3•2b 5.02
a P < 0.001; b p < 0.01; C P < 0.05 compared to Period A (paired
t-test)
Biochemical determinations
Routine chemistries were performed by routine laboratory
methods adjusted for the Technicon Auto Analyzer (Technicon
Instruments Corporation, Tarrytown, New York, USA).
Recirculation studies
In order to determine the adequacy of fistula flow rates, BUN
levels were determined by simultaneously sampling blood from
the arterial and venous ports of dialyzer tubing and from a
contralateral vein. Recirculation studies were performed within
15 minutes following the initiation of dialysis. The percent
recirculation is given by the formula:
(peripheral BUN — arterial BUN/peripheral BUN
Statistics
— venous BUN) X 100
Statistical analysis was performed using the Student's t-test
for paired or unpaired data and by correlation analysis. All
results are reported as the mean
Results
During routine urea kinetic analysis, we noted that the
percent of patients with urea clearances less than 200 mllmin
was 48% (Period B). Review of kinetic analysis performed two
months prior to this revealed that only 5% had urea clearances
in this range (Period A). Three patients complained of nausea
and increased somnolence. Recirculation studies on the af-
fected subjects showed no evidence of reduced fistula function,
as defined by less than 15% admixture. Routine pre-dialysis
chemistries of the affected and unaffected groups during these
two periods are summarized in Table 1. There were no signifi-
cant changes in plasma creatinine, BUN, or potassium in the
unaffected group. In the affected group, however, all biochem-
ical determinations rose significantly from Period A to Period B.
Because of the evidence of widespread dialyzer dysfunction,
all patients were switched to new dialyzers and reprocessing
was continued. Measurements of urea clearances were repeated
within a week. In those 48 patients with urea clearances less
than 200 mI/mm, the clearance rose from 150 5 to 256 6
mI/mm (P < 0.001). In those 51 patients with clearness greater
than 200 mI/mm, there were no differences (241 5 vs. 240
4 mI/mm). Thus, the improvement in clearances in the former
group did not represent a regression toward the mean. The data
are summarized on Figure 1. There was no correlation between
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Initial Clearances
clearances following
dialyzer
change
Fig. 1. Urea clearances derived from urea kinetics in patients with
clearances less than 200 mI/mm (•) and in patients with clearances
greater than 200 ml/min (A). Repeat measurements performed follow-
ing the change to new dialyzers revealed a marked improvement in
clearances (*P < 0.001) in those with low initial clearances whereas
there was no difference in those with intact dialyzer function.
reuse number and urea kinetic-derived clearances in either
group.
Two months following the change to different lots of TAF 12
and TAF 10 dialyzers and continued reprocessing, urea kinetics
were remeasured in all patients. Impaired clearances in some
patient were again noted. This was traced to one lot of TAF 12
dialyzers. All dialyzers in that lot were then studied in vitro
using conductivity clearances. Twenty-five out of 37 dialyzers
in the lot demonstrated reductions in clearances of greater than
10% of the manufacturer's specification. The mean clearances
were 161 8 mi/mm which compared to 220 2 mI/mm in the
12 dialyzers with sustained function. The clearance of the entire
% Fall in clearance
in vivo
Fig. 2. Correlation analysis of the relation between the % fall in
predicted clearances determined in vitro using conductivity methodol-
ogy and those derived from in vivo derived urea kinetics in a lot of
dysfunctional TAF 12 dialyzers (A,———) and TAF 10 dialyzers (•,—).
A strong relationship was found for each lot (Y = 0.51 X + 12.2, r =
0.610, P < 0.01 and Y = 0.76 X + 1.4, r = 0.838, P < 0.001,
respectively).
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lot was 180 7 ml/min. Urea kinetic-derived and in vitro
clearances were compared in 21 of 25 of the dialyzers and a
close correlation was seen (Fig. 2). There were no differences in
the reuse number in those dialyzers with impaired and normal
clearances (15 1 vs. 14 1, respectively). The in vitro
clearances of a different lot of TAF 12 dialyzers reprocessed 21
3 times were all normal (223 2 mI/mm, N = 12). These were
significantly higher (P < 0.001) than those clearances of the
affected 25. Similarly, the in vitro clearances of a lot of TAF 10
dialyzers (N = 20) were reduced to 147 II mI/mm following
12 4 reuses. This compared to clearances of 207 3 mI/mm
in a separate lot of TAF 10 dialyzers (N = 11, P < 0.001)
measured following 21 5 reuses. The reduction in in vitro
clearances of the dysfunctional TAF 10 dialyzers also cone-
lated with those found in vivo. This relationship is shown in
Figure 2. The same lot of TAF 10 dialyzers was also utilized at
our satellite unit that employs a different reprocessing proce-
dure (Methods). The in vitro clearances of these seven dialyzers
were 144 21 mI/mm following 13 1 reprocessing treatments.
These values were not different from those obtained with the
same lot at Chromalloy American Kidney Center. Therefore the
impaired function resulted from an intrinsic abnormality of the
dialyzers and not from the type of reprocessing equipment
utilized. These data are summarized in Figure 3.
Because all dialyzers that demonstrated severe dysfunction
passed the standard validation tests, we hypothesized that there
was maldistribution of flow between the blood and dialysate
paths. In order to test this possibility, dialyzers with severe
dysfunction were tested on a Centry 2 dialysis machine in vitro
by injecting methylene blue into the dialysate port. As can be
seen from Figure 4, there was non-uniform flow of dialysate
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Fig. 3. The effects of reprocessing systems and lot characteristics on
conductivity clearance. Despite being treated by two distinctly different
processes, dialyzers from a lot with low in vivo clearances (nj), did not
have different conductivity clearances. In contrast, dialyzers from a lot
demonstrating normal in vivo function (•) showed higher in vitro
clearances (P <0.001) despite undergoing reprocessing with one of the
same systems (DRS 4).
along one side of the dialyzer (channeling). This was present in
most, but not all, of the affected dialyzers. In comparison, the
uniform flow of methylene blue in a non-affected dialyzer is
shown in Figure 5.
In order to better define the mechanism of dialyzer dysfunc-
tion, further in vitro studies of seven TAF 12 dialyzers in a lot
associated with poor clearances (lot #1) and seven dialyzers
associated with intact clearances (lot #2) were performed. The
clearances of the unused dialyzers in lot #1 and #2 were not
different (Fig. 6). However, when retested after five daily
reprocessing treatments (and storage in glutaraldehyde), the
clearances of the dialyzers in lot #1 fell from 217 4 to 128
11 ml/min (P < 0.001). After reprocessing 15 times, the clear-
ances were 111 18 mI/mm. No changes were noted in the
dialyzers from lot #2 reprocessed 15 times (225 2 vs. 229
Fig. 4. Injection of inethylene blue into the dialysate port of a dialyzer
with markedly impaired urea clearances in vivo. There was marked
maldistribution of flow with the path of the dye being confined to one
side of the dialyzer.
2). The TCV of each lot of dialyzers, measured by the DRS 4
reprocessor, were not different after 15 reprocessing proce-
dures (lot #1, 84 I ml; lot #2, 83 I ml). The TCV of the
same dialyzers in lot #1 were 84 I and lot #2, 82 1 ml,
when measured manually.
Because the major impairment in clearances appeared to
occur by the first five reprocessing treatments, serial ciearances
were performed after 0, 1, 3, and 5 reuses in seven dialyzers
from lot #1. As shown in Figure 7, reprocessing a single time
lead to a mean decline in clearances of 11% (218 9 vs. 195
7 mI/mm). After reprocessing five times, the clearance declined
to 151 16 mI/mm. It was also obvious that there was
considerable variability in clearances of dialyzers in lot #1.
Because the dialyzers were soaked in 0.8% glutaraldehyde
between each reprocessing procedure, we investigated the
effect of soaking eight dialyzers in lot #1 in the same solution
for a period of five days. As can be seen in Figure 8, soaking
also led to a decline in clearance. The fall, from 224 4 to 197
4 mI/mm, however, was not as great as that of reprocessing
(P < 0.02). Although glutaraldehyde may form polymers and
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cause fiber adherence, it could also hydrate the fibers causing
changes in their size or geometry. We therefore soaked eight
dialyzers in standard dialysate for five days. The clearances
decreased 11% from 223 3 to 192 6 ml/min (Fig. 8). The
latter values were significantly less than control measurements
(P < 0.001) but greater than those measured after five daily
reprocessing procedures (P < 0.02). No changes in clearances
due to soaking in dialysate were noted in lot #2 (226 I vs. 223
2 mI/mm). Hence, the effects of the glutaraldehyde solution
on dialyzer function may have resulted from hydration of the
hollow fibers rather than a property unique to that compound.
Discussion
It is frequently stated in texts [8, 9] that clearances by
dialyzer are unaffected by reuse if proper standards for rejec-
tion are followed. Ferrell et al [10], for example, found a good
correlation between TCV and clearances. Gotch [11] noted a
similar correlation. Others [12—14] were able to correlate UFR
and clearance. We employed both these parameters as well as
visual inspection and fiber leak but, nonetheless, encountered
an epidemic of dialyzer dysfunction. Although Vanholder et a!
reported mild decreases in clearances in some dialyzers with up
Reprocess number
Fig. 6. Serial conductivity clearances of dialyzers in a lot associated
with low clearances in vivo (lot #1, •) and of those from a lot with
intact clearances (lot #2, 0). The clearances of unused dialyzers were
the same in the two lots. However, followings reprocessing treatments,
the clearances of dialyzers in lot #1 fell significantly (P < 0.001) and
continued to decline after 10 and 15 treatments. No changes in
clearances were noted in the dialyzers from lot #2. All maneuvers were
performed in vitro without exposure of the dialyzers to patients.
to 7 reuses F15], to the best of our knowledge, the severity and
prevalence of the problem we encountered is unprecedented. It
should be emphasized that our data concerns only dialyzers
with cuprophane membranes and may not apply to other types
of dialyzers. Although we do not believe that the type of
disinfectant plays a significant role in causing dialyzer dysfunc-
tion, the findings also may not be relevant to reprocessing
systems utilizing formaldehyde.
The etiology of the damage to the dialyzers was probably
multifactorial. The in vitro and in vivo studies showed that
three lots of dialyzers were adversely affected by reprocessing
whereas other lots were not affected. The large variability in
declining clearances in lot #1 may explain the lack of correla-
tion between in vivo clearances and number of reuses. There
were, however, good correlations between declines in in vivo
and in vitro clearances in two separate lots of dialyzers. The
findings of channeling in the severely affected dialyzers, may
account, in part, for the absence of alterations in TCV or KUF
in the dialyzers. One would think, a priori, that maldistribution
of flow between blood and dialysate would have the potential to
diminish clearances without affecting these parameters. The
decrease in clearances following soaking dialyzers in lot #1 is of
interest. It is postulated that wetting the fibers caused expan-
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Fig. 5. Injection of methylene blue into the dialysate port of a dialyzer
associated with intact urea clearances in vivo. Note the uniform pattern
of flow of the dye as it traverses the dialyzer.
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Fig. 7. Serial conductivity clearances in dialyzers from lot #1 exposed
to 0, 1, 3, and 5 reprocessing treatments. A decline in clearances was
noted in all dialyzers after one treatment which progressed following
subsequent treatments.
sion and elongation. This, in turn, could predispose to channel-
ing. The exact cause of the dialyzer malfunction is unknown.
Conceivably, errors in fiber length, geometry or number could
lead to distortion. Because reprocessing was associated with
lower clearances than those of soaking in glutaraldehyde or
dialysate, it is likely that it further potentiated fiber deformity in
those predisposed dialyzers. This may have been due to the
high negative transmembrane pressures present during the
cleaning cycle. It should be noted, however, that the Seratron-
ics reprocessing system utilizes 1200 mm Hg of pressure
whereas the Renatron system employs 250 mm Hg. Nonethe-
less, reprocessing with either system appeared to decrease
clearances in one lot to the same extent. This suggests that the
degree of predisposition to develop dialyzer dysfunction during
reprocessing may be of greater importance than the type of
reprocessing system.
Reuse is generally a safe and reliable method to treat patients
with renal failure [16]. Robson et al [171 report fewer episodes
of hypotension, cramps, nausea or vomiting, headache, itching,
chest pain and back pain when patients are dialyzed with reused
dialyzers compared to those used for the first time. Presumably
I I
0 5
Time, days
Fig. 8. The effects of soaking dialyzers from lot #1 in dialysate or
g!u:araldehyde on conductivity clearances. Symbols are: (Li) soak in
glutaraldehyde; () soak in dialysate; (•) reuse. After 5 days, soaking
in either solution led to an 11% decline in clearance. This was less than
that seen after 5 days of daily reprocessing with glutaraldehyde storage(P < 0.02). There were no effects of soaking in either solution on
clearances in dialyzers from lot #2 (data not shown).
these effects are due to decreased complement activation and
neutropenia seen in reprocessed cuprophane dialyzers [18].
Until the prevalence of inapparent severe dialyzer dysfunc-
tion during reprocessing is known, any comprehensive recom-
mendations concerning reprocessing beyond those of AAMI
[19] would be ill-advised. Clearly, however, one should be
aware of the potential for occurrence. Any unexplained wors-
ening of patients' symptoms, chemistries, or urea kinetics
warrant immediate investigation. In addition, spot checks of the
in vitro clearances of reprocessed dialyzers should afford an
additional level of safety.
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